1. Home
  2. EKSO vs APLM Comparison

EKSO vs APLM Comparison

Compare EKSO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EKSO
  • APLM
  • Stock Information
  • Founded
  • EKSO 2005
  • APLM 2016
  • Country
  • EKSO United States
  • APLM United States
  • Employees
  • EKSO N/A
  • APLM N/A
  • Industry
  • EKSO Medical/Dental Instruments
  • APLM Blank Checks
  • Sector
  • EKSO Health Care
  • APLM Finance
  • Exchange
  • EKSO Nasdaq
  • APLM Nasdaq
  • Market Cap
  • EKSO 13.4M
  • APLM 12.3M
  • IPO Year
  • EKSO N/A
  • APLM N/A
  • Fundamental
  • Price
  • EKSO $0.65
  • APLM $9.56
  • Analyst Decision
  • EKSO Strong Buy
  • APLM Strong Buy
  • Analyst Count
  • EKSO 2
  • APLM 2
  • Target Price
  • EKSO $5.50
  • APLM $425.00
  • AVG Volume (30 Days)
  • EKSO 2.9M
  • APLM 36.2K
  • Earning Date
  • EKSO 03-03-2025
  • APLM 02-15-2025
  • Dividend Yield
  • EKSO N/A
  • APLM N/A
  • EPS Growth
  • EKSO N/A
  • APLM N/A
  • EPS
  • EKSO N/A
  • APLM N/A
  • Revenue
  • EKSO $17,682,000.00
  • APLM $2,101,000.00
  • Revenue This Year
  • EKSO $1.11
  • APLM N/A
  • Revenue Next Year
  • EKSO $38.63
  • APLM N/A
  • P/E Ratio
  • EKSO N/A
  • APLM N/A
  • Revenue Growth
  • EKSO 4.12
  • APLM 70.54
  • 52 Week Low
  • EKSO $0.50
  • APLM $6.50
  • 52 Week High
  • EKSO $2.50
  • APLM $91.00
  • Technical
  • Relative Strength Index (RSI)
  • EKSO 46.63
  • APLM 46.48
  • Support Level
  • EKSO $0.62
  • APLM $9.50
  • Resistance Level
  • EKSO $1.00
  • APLM $10.67
  • Average True Range (ATR)
  • EKSO 0.12
  • APLM 0.92
  • MACD
  • EKSO 0.00
  • APLM -0.04
  • Stochastic Oscillator
  • EKSO 19.79
  • APLM 13.17

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: